ArticleClinical & experimental metastasis2020
Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases.
Article in Clinical & experimental metastasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.The journal of pathology. Clinical research · 2022Trial
- Spatial transcriptomics differences of histopathological growth patterns in colorectal cancer liver metastases.British journal of cancer · 2026Article
- Encapsulated histopathological growth pattern of colorectal liver metastases predicts prolonged survival after repeat liver resection for recurrence.Clinical & experimental metastasis · 2026Article
- Examination of histopathological growth patterns of liver metastases in a retrospective, consecutive, single-center, cohort study.Pathology oncology research : POR · 2025Article
- Impact of pure desmoplastic histological growth patterns in colorectal liver metastasis.BMC cancer · 2024Article
- Classifying histopathological growth patterns for resected colorectal liver metastasis with a deep learning analysis.BJS open · 2024Article
- Microscopic Growth Pattern of Metastatic Colorectal Carcinomas, Morphological Findings of the Non-Neoplastic Liver, and Their Relationship With Prognosis and Survival.International journal of surgical pathology · 2024Article
- Consideration on immunotherapy of liver metastases of malignant tumors.World journal of gastrointestinal surgery · 2024Article
- Prediction of transformation in the histopathological growth pattern of colorectal liver metastases after chemotherapy using CT-based radiomics.Clinical & experimental metastasis · 2024Article
- Role of stromal PD-L1 expression in colorectal liver metastasis.BMC cancer · 2024Article
- Adjuvant Hepatic Artery Infusion Chemotherapy: Still Swimming in Dark Water?Annals of surgical oncology · 2024Article
- The Effect of Histopathological Growth Patterns of Colorectal Liver Metastases on the Survival Benefit of Adjuvant Hepatic Arterial Infusion Pump Chemotherapy.Annals of surgical oncology · 2023Article
- A CT-based radiomics nomogram for predicting histopathologic growth patterns of colorectal liver metastases.Journal of cancer research and clinical oncology · 2023Article
- Histopathological growth patterns of neuroendocrine tumor liver metastases.Clinical & experimental metastasis · 2023Article
- Prognostic Significance of the Histopathological Growth Pattern and Tumor-Infiltrating Lymphocytes in Stratifying Survival After Hepatectomy for Colorectal Liver Metastases.Annals of surgical oncology · 2023Article
- Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment.Cancers · 2022Review
- The relationship between primary colorectal cancer histology and the histopathological growth patterns of corresponding liver metastases.BMC cancer · 2022Article
- Clinical implications and mechanism of histopathological growth pattern in colorectal cancer liver metastases.World journal of gastroenterology · 2022Review
- Histopathological growth patterns of resected non-colorectal, non-neuroendocrine liver metastases: a retrospective multicenter study.Clinical & experimental metastasis · 2022Article
- Contemporary evidence on colorectal liver metastases ablation: toward a paradigm shift in locoregional treatment.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 3 countries.
Funding
Abstract
Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemotherapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000-2016). A total of 656 patients (53.1%) patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37-0.73, p < 0.001), and not in desmoplastic patients (adjusted HR 1.78, 95% CI 0.75-4.21, p = 0.19). In pretreated patients no significant effect of adjuvant CTx was observed, neither in the desmoplastic group (adjusted HR 0.83, 95% CI 0.49-1.42, p = 0.50) nor in the non-desmoplastic group (adjusted HR 0.96, 95% CI 0.71-1.29, p = 0.79). Similar results were found for DFS, with a superior DFS in non-desmoplastic patients treated with adjuvant CTx (HR 0.71, 95% CI 0.55-0.93, p < 0.001) that were not pretreated. Adjuvant CTx seems to improve OS and DFS after resection of non-desmoplastic CRLM. However, this effect was only observed in patients that were not treated with chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.